Please login to the form below
hematology
This page shows the latest hematology news and features for those working in and with pharma, biotech and healthcare.
A first for Bluebird and Europe as gene therapy Zynteglo approved
The approval comes just days ahead of a number of important phase 3 read outs for Zynteglo at the European Hematology Association (EHA) congress in Amsterdam.
Latest news
-
J&J’s targeted bladder cancer treatment gets US approval
with advances being made in new disease types,” said Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products
-
Darzalex powers ahead with frontline myeloma approval in Europe
first investigator to administer daratumumab in human trials and Professor, head of the department of hematology at Vejle Hospital, Denmark.
-
China’s BeiGene takes PD-1 antibody into pivotal trials
Jane Huang. , M.D., Chief Medical Officer, Hematology, at. BeiGene (pictured).
-
More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
While the US-based ASCO and ASH congresses tend to get the most important haemato-oncology and blood disorder data readouts, the European Hematology Association (EHA) congress now under way in
-
FDA clears Dova drug for liver-related low blood platelets
Hematology and Oncology Products at the FDA.
More from news
Approximately 6 fully matching, plus 49 partially matching documents found.
Latest Intelligence
-
Attracting doctors to low-demand specialties
A brief glance at the programme for the major US haematology congress, held by the American Society of Hematology, tells its own story, with most sessions being dedicated to haematological malignancies
-
Deal Watch November 2016
This does not typically include royalty payments. 2. Ataga et al, Abstract, American Society of Hematology (ASH), December 2016.
-
Deal Watch July 2016
Portfolio of early-stage hematology candidates &option for recombinant pegasparaginase. Licence, option.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Nanobiotix strengthens US leadership team
Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.
-
TxCell appoints global scientific advisory board
Prof Chiara Bonini (pictured left) is currently head of the experimental hematology unit at the San Raffaele Scientific Institute, a position she has held since 2008.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Highlights in haematologic malignancy from ASH 2018
Earlier this month, Porterhouse Medical attended the 60. th. American Society of Hematology (ASH) Annual Meeting (). The ASH congress is the most comprehensive haematology event of the year, attracting 25, 000
-
Random42 Attending ASH Annual Meeting in San Diego
Now in its 60th year the American Society of Hematology (ASH) annual meeting and exposition is the premier event in malignant and non-malignant hematology. ... The meeting provides an invaluable educational experience and the opportunity to review
-
Increasing the speed of knowledge sharing in blood cancer to improve patient care
Society of Hematology XXXVI World Congress in Congress ( ISH), which was hosted by the British Society for Haematology at the 56th Annual Scientific Meeting, between 18th-21st April.
-
Lighthouse Medical Communications US bolster their senior scientific team
number of key therapeutic areas such endocrinology, neurology, oncology, hematology, women’s health and rare diseases.
-
Attracting doctors to low-demand specialties: A role for industry?
A brief glance at the programme for the major US haematology congress, held by the American Society of Hematology, tells its own story, with most sessions being dedicated to haematological malignancies
More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
